PubMed Journals Articles About "GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary" RSS

10:08 EST 1st March 2015 | BioPortfolio

GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary articles that have been published worldwide.

More Information about "GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary" on BioPortfolio

We have published hundreds of GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary news stories on BioPortfolio along with dozens of GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary Clinical Trials and PubMed Articles about GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary Companies in our database. You can also find out about relevant GSK573719 GW642444 GSK573719 GW642444 GW642444 Tiotropium Bromide Pulmonary Drugs and Medications on this site too.

Showing "GSK573719 GW642444 GSK573719 GW642444 GW642444 tiotropium bromide Pulmonary" PubMed Articles 1–25 of 3,600+

Extremely Relevant

Effect of inhaled tiotropium on spirometric parameters in patients with tuberculous destroyed lung.

In Korea, patients with destroyed lung due to tuberculosis (TB) account for a significant portion of those affected by chronic pulmonary function impairment. The objective of our research was to evaluate the efficacy of inhaled tiotropium bromide in TB destroyed lung.

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years.

Aclidinium bromide is a long-acting muscarinic antagonistic used in maintenance treatment of chronic obstructive pulmonary disease (COPD). A model-based health economic study evaluated the cost-effectiveness of aclidinium 400 μg bid as an alternative to tiotropium 18 μg od for this indication in the US.

Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends.

Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting beta2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide and umeclidinium bromide, are administered once daily, whereas aclidinium bromide is administered every 12 hours. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24-h dur...

Effect of Tiotropium on Hyperinflation and Treadmill Exercise Tolerance in Mild-Moderate Chronic Obstructive Pulmonary Disease.

Rationale: Bronchodilator therapy represents a potentially valuable therapeutic option to increase exercise tolerance and enhance lung function in mild-to-moderate chronic obstructive pulmonary disease (COPD). Objectives: To determine effects of tiotropium on pulmonary hyperinflation and exercise tolerance in symptomatic Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 and 2 COPD patients who experienced inspiratory capacity decrease ≥100 mL during incremental and constant work rate treadmi...

Clinical use of aclidinium in patients with COPD.

Chronic obstructive pulmonary disease (COPD) is the sixth-leading cause of death in the US. The Global initiative for Chronic Obstructive Lung Disease (GOLD) guidelines provide evidence-based recommendations for the clinical management of chronic COPD. Long-acting inhaled bronchodilators continue to be the mainstay of current management. Aclidinium bromide (Tudorza™ Pressair™) joins tiotropium as a long-acting inhaled antimuscarinic bronchodilator approved by the US Food and Drug Administration for the ...

Safety, Tolerability, and Plasma Exposure of Tiotropium Respimat(®) in Children and Adults with Cystic Fibrosis.

Abstract Background: People with cystic fibrosis (CF) suffer from chronic lung disease that is often treated with a bronchodilator. This trial evaluated the pharmacokinetics, safety, and tolerability of single and multiple doses of tiotropium inhaled via the Respimat(®) Soft Mist™ Inhaler in patients with CF. Methods: Patients received a single dose (placebo, 2.5 μg, 5 μg, or 10 μg) and/or multiple doses (placebo, 2.5 μg, or 5 μg) of tiotropium daily for 28 days. Results: Ninety-two patien...

Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.

Combining bronchodilators with different mechanisms of action may improve efficacy and reduce risk of side effects compared to increasing the dose of a single agent in chronic obstructive pulmonary disease (COPD). We investigated this by combining two long-acting bronchodilators: once-daily muscarinic antagonist tiotropium and once-daily β2-agonist olodaterol.

Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats.

The compound series of traditional anticholinergics [atropine (Atr), anisodamine (Ani), anisodine (AT3), and scopolamine (Sco)], naturally occurring belladonna alkaloid, have been approved for numerous therapeutic uses since 1970s. Tiotropium, a novel M receptor antagonist for the treatment of chronic obstructive pulmonary disease, was structurally modified based on atropine-like drugs. Clinical phenomena suggested that the changes of substituent group were related to the pharmacokinetic and pharmacodynamic...


The role of tiotropium for the treatment of asthma has not yet been clearly defined. The aim of this systematic review was to assess the efficacy and safety of tiotropium in asthma patients.

Tiotropium Delivered via HandiHaler or Respimat: Improvement in Health-Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease.

COPD Treatment PostersSESSION TYPE: Original Investigation PosterPRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PMPURPOSE: To assess the effects of maintenance therapy with tiotropium, a long-acting anticholinergic, on health-related quality of life (HRQoL) in COPD patients using data from 16 clinical trials.METHODS: Trials included patients with moderate-to-very severe COPD, ≥40 years, smoking history >10 pack-years. Tiotropium was delivered via HandiHaler® (Tio HH; 13 trials) or Respi...


Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results.

Tiotropium is a once-daily, long-acting anticholinergic bronchodilator with the potential to alleviate airway obstruction in cystic fibrosis. Our objective was to evaluate the efficacy and safety of 2.5 and 5 µg once-daily tiotropium delivered via the Respimat Soft Mist Inhaler vs. placebo in people with cystic fibrosis.

Combined Use of Olodaterol Respimat and Tiotropium HandiHaler Shows Additional Lung Function Improvement in COPD Compared With Tiotropium: Results From Two Randomized, Double-Blind Studies.

Original Investigation SlidePRESENTED ON: Monday, October 27, 2014 at 01:30 PM - 02:30 PMPURPOSE: To evaluate the bronchodilator effectiveness of combining two classes of long-acting bronchodilators (tiotropium and olodaterol) in separate devices in clinically stable patients with chronic obstructive pulmonary disease (COPD).METHODS: In two replicate, double-blind, randomized, 12-week studies, we compared the effects of (a) olodaterol 5 µg once daily (qd) (via Respimat®) in combination with tiotropium 18 ...

Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.

In patients with severe asthma, tiotropium improves lung function and exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting β2 agonists. We aimed to assess the safety and efficacy of tiotropium in patients with moderate asthma who were symptomatic despite treatment with medium-dose inhaled corticosteroids.

Health Status of Patients With COPD Receiving the Combination of Olodaterol Respimat and Tiotropium HandiHaler Compared With Tiotropium: Results From Two Replicate, Randomized, Double-Blind Studies.

COPD Treatment PostersSESSION TYPE: Original Investigation PosterPRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PMPURPOSE: To determine whether combining long-acting β-agonists (LABAs) with long-acting muscarinic antagonists (LAMAs) once daily will improve the health status of patients with chronic obstructive pulmonary disease (COPD).METHODS: We report on two replicate, double-blind, randomized, 12-week studies comparing the effects of (a) the free combination of the LABA olodaterol 5 µg o...

Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease.

Umeclidinium/vilanterol (Anoro(®) Ellipta™; Laventair™) is an inhaled fixed-dose combination of a long-acting muscarinic receptor antagonist and a long-acting β2-adrenoceptor agonist. It is available in several countries, including Japan, the USA, Canada and those of the EU, where it is indicated for oral inhalation in adults with chronic obstructive pulmonary disease (COPD). Umeclidinium/vilanterol is administered once daily using the Ellipta™ multi-dose dry powder inhaler, which is regarded as eas...

Tiotropium in the Treatment of Patients with Asthma.

Asthma is a chronic disease with a significant disease burden, and many patients fail to achieve disease control despite recommended medical therapy. Recent evidence suggests that there may be benefits to the use of the long-acting anticholinergic agent tiotropium in patients with asthma.

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.

Long-acting bronchodilators are the preferred option for maintenance therapy of patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the clinical efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium bromide in patients suffering from COPD.

Pulmonary embolism and tuberculosis.

Tuberculosis has a high prevalence in Tunisia, but pulmonary embolism is rarely reported in Mycobacterium tuberculosis infection. We describe 3 cases of pulmonary embolism associated with severe pulmonary tuberculosis. Pulmonary embolism occurred within 2 to 13 days of pulmonary tuberculosis diagnosis. Clinical, bacteriological, and radiological evolutions were noted within 6 months for pulmonary tuberculosis, but controlling the international normalized ratio was difficult in 2 cases, and low-molecular-wei...

A critical evaluation of bioimpedance spectroscopy analysis in estimating body composition during GH treatment: comparison with bromide dilution and dual X-ray absorptiometry.

Objective: To compare estimates by Bioimpedance Spectroscopy Analysis (BIS) of extracellular water (ECW), fat mass (FM), and fat free mass (FFM) against standard techniques of bromide dilution and DXA during intervention that causes significant changes in water compartments and body composition. Methods: Body composition analysis using BIS, bromide dilution, and DXA was performed in 71 healthy recreational athletes (43 men, 28 women; aged 18-40 years; BMI 24±0.4 kg/m2) who participated in a double-blinded,...

T-type calcium channels are involved in hypoxic pulmonary hypertension.

Pulmonary hypertension (PH) is the main disease of pulmonary circulation. Alteration in calcium homeostasis in pulmonary artery smooth muscle cells (PASMC) is recognized as a key feature in PH. The present study was undertaken to investigate the involvement of T-type voltage gated calcium channels (T-VGCC) in the control of the pulmonary vascular tone and thereby in pulmonary hypertension development.

An Octogenarian Diagnosed With Idiopathic Pulmonary Artery Dilatation.

Pulmonary Vascular Disease CasesSESSION TYPE: Affiliate Case Report SlidePRESENTED ON: Monday, October 27, 2014 at 03:15 PM - 04:15 PMINTRODUCTION: Pulmonary artery dilatation is mostly associated with both primary and secondary pulmonary hypertension, connective tissue diseases, pulmonary valve stenosis and congenital heart disease. Idiopathic pulmonary artery dilatation (IPAD) is a rare entity in the literature.

Seasonal Variations in Mortality and Exacerbations in Patients With Chronic Obstructive Pulmonary Disease During the TIOSPIR Trial.

COPD Exacerbation RiskSESSION TYPE: Original Investigation SlidePRESENTED ON: Wednesday, October 29, 2014 at 02:45 PM - 04:15 PMPURPOSE: To examine seasonal variations in mortality and exacerbations in COPD patients in the TIOtropium Safety and Performance In Respimat® (TIOSPIR®) trial (NCT01126437).

The Selective Oxidation of Alcohols Using Alkali Metal Bromides as Bromide Catalysts: A Experimental Study of the Reaction Mechanism.

A bromide-catalyzed oxidation of alcohols was developed which proceeded in the presence of an alkali metal bromide and an oxidant under mild conditions. The reaction involved an organic-molecule-free oxidation using KBr and Oxone® and a Bronsted-acid-assisted oxidation using KBr and aqueous H2O2 solution to provide a broad range of carbonyl compounds in high yields. Moreover, the bromide-catalyzed oxidation of primary alcohols enabled the divergent synthesis of carboxylic acids and aldehydes under both rea...

Can echocardiographically estimated pulmonary arterial elastance be a non-invasive predictor of pulmonary vascular resistance?

Measurement of pulmonary vascular resistance (PVR) is essential in evaluating a patient with pulmonary hypertension.

Pulmonary Artery Sarcoma: Not Every Filling Defect Is a Pulmonary Thromboembolism.

Pulmonary Vascular Case Report PostersSESSION TYPE: Affiliate Case Report PosterPRESENTED ON: Tuesday, October 28, 2014 at 01:30 PM - 02:30 PMINTRODUCTION: Pulmonary artery sarcoma (PAS) is a rare malignancy arising from the mesenchymal cells of the intima of pulmonary artery.It is often misdiagnosed as pulmonary thromboembolism (PTE), as both diseases initially appear as intraluminal 'filling defects' in the pulmonary artery on contrast-enhanced CT scans. We describe a patient initially misdiagnosed as PTE...

Search BioPortfolio:

PubMed Database Quicklinks